Alivus Life Sciences Limited has filed a regulatory disclosure with BSE Ltd. and the National Stock Exchange of India Ltd. regarding the acquisition of a controlling stake in IQGEN-X Pharma Private Limited.
The company references its previous communication dated August 18, 2026, regarding a share purchase agreement to acquire a 76% stake in IQGEN-X.
The disclosure confirms that the closing process under the Share Purchase Agreement has been initiated. The company has acquired 7,36,096 equity shares of IQGEN-X, representing 65.01% of its issued and paid-up equity share capital. The remaining share capital of IQGEN-X will be acquired in due course.
As a result of this acquisition, IQGEN-X Pharma Private Limited has become a subsidiary of Alivus Life Sciences Limited effective November 11, 2026.
The intimation is made specifically pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, for information and records of the stock exchanges.